NEW YORK ( TheStreet) -- Teva Pharmaceutical ( TEVA) -- founded in 1901 and headquartered in Israel -- is a worldwide pharmaceutical company with a mission to be "the most indispensible medicines company in the world."Teva works across the board to develop, produce and market a wide range of products within specialty medicines, generic and over-the-counter products, active pharmaceutical ingredients and new therapeutic entities. In the United States alone, Teva markets approximately 400 generic products in about 1,300 dosage strengths. The company also operates in 59 other countries across Europe and the rest of the world, and is perhaps best known for Copaxone, which is used to treat multiple sclerosis. For those unfamiliar with the business behind the company, we can instantly look at Teva's past operating results through the lens of F.A.S.T. Graphs. Here a picture is truly worth a magnitude of words. We see that Teva has grown operating earnings by nearly 24% a year for the past decade and a half and demonstrated a commitment to increasing the dividend while simultaneously keeping the earnings payout ratio quite low. Additionally, it should be noted that Teva had exceptional earnings per share growth in the early 2000s and has since begun to moderate a bit. To be fair, even recently this pharmaceutical company has been able to grow earnings at a double-digit rate.